scispace - formally typeset
R

Rui-Ru Ji

Researcher at Bristol-Myers Squibb

Publications -  22
Citations -  15288

Rui-Ru Ji is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Ipilimumab & Genome. The author has an hindex of 11, co-authored 20 publications receiving 14671 citations. Previous affiliations of Rui-Ru Ji include Ohio State University & Celera Corporation.

Papers
More filters
Journal ArticleDOI

The sequence of the human genome.

J. Craig Venter, +272 more
- 16 Feb 2001 - 
TL;DR: Comparative genomic analysis indicates vertebrate expansions of genes associated with neuronal function, with tissue-specific developmental regulation, and with the hemostasis and immune systems are indicated.
Journal ArticleDOI

The Sequence of the Human Genome

J. Craig Venter, +272 more
- 01 Sep 2015 - 
TL;DR: Comparative genomic analysis indicates vertebrate expansions of genes associated with neuronal function, with tissue-specific developmental regulation, and with the hemostasis and immune systems are indicated.
Journal ArticleDOI

An immune-active tumor microenvironment favors clinical response to ipilimumab

TL;DR: These results support the proposed mechanism of action of ipilimumab, suggesting that cell-mediated immune responses play an important role in the antitumor activity of ipILimumab.
Journal ArticleDOI

A Comparison of Whole-Genome Shotgun-Derived Mouse Chromosome 16 and the Human Genome

Richard J. Mural, +174 more
- 31 May 2002 - 
TL;DR: Comparison of the structure and protein-coding potential of Mmu 16 with that of the homologous segments of the human genome identifies regions of conserved synteny with human chromosomes (Hsa) 3, 8, 12, 16, 21, and 22.
Journal ArticleDOI

Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events

TL;DR: Gene expression profiling of peripheral blood, sampled before or early in the course of treatment with ipilimumab, resulted in the identification of a set of potential biomarkers that were associated with occurrence of GI irAEs, but because of the low sensitivity of these biomarkers, they cannot be used alone to predict which patients will develop GI ir AEs.